Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma
Primary Purpose
Ocular Surface Disease, Glaucoma
Status
Unknown status
Phase
Not Applicable
Locations
Thailand
Study Type
Interventional
Intervention
hydroxypropylmethylcellulose
sodium hyaluronate
Sponsored by
About this trial
This is an interventional treatment trial for Ocular Surface Disease
Eligibility Criteria
Inclusion Criteria:
- OSDI > or equal 20 and eye lid inflammation , meibomian gland inflammation,conjunctival injection,follicle at tarsus , positive corneal staining , tear break up time less than 8 seconds , tear volume less than 5.5 mm.
Exclusion Criteria:
- Age below 18 yo
- Active infectious corneal disease
- Post penetrating keratoplasty or glaucoma drainage device
- Known allergy to medication
- Lactation , Pregnant
Sites / Locations
- Department of Ophthalmology , Siriraj HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
TearA
TearB
Arm Description
Outcomes
Primary Outcome Measures
Ocular surface index score
Secondary Outcome Measures
Eye lid inflammation, corneal staining score, tear break up time and tear volume
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01284439
Brief Title
Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma
Official Title
Effect of Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% in the Treatment of Ocular Surface Disease in Glaucoma Patients
Study Type
Interventional
2. Study Status
Record Verification Date
January 2011
Overall Recruitment Status
Unknown status
Study Start Date
January 2011 (undefined)
Primary Completion Date
January 2012 (Anticipated)
Study Completion Date
February 2012 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Mahidol University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To study effect of hydroxypropylmethylcellulose 0.3% and sodium hyaluronate 0.18% in the treatment of ocular surface disease in glaucoma patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ocular Surface Disease, Glaucoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
TearA
Arm Type
Experimental
Arm Title
TearB
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
hydroxypropylmethylcellulose
Intervention Description
TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
Intervention Type
Drug
Intervention Name(s)
sodium hyaluronate
Intervention Description
QID to every 2 hous, 1-2 drops per each time, duration 1 month
Primary Outcome Measure Information:
Title
Ocular surface index score
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Eye lid inflammation, corneal staining score, tear break up time and tear volume
Time Frame
1 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
OSDI > or equal 20 and eye lid inflammation , meibomian gland inflammation,conjunctival injection,follicle at tarsus , positive corneal staining , tear break up time less than 8 seconds , tear volume less than 5.5 mm.
Exclusion Criteria:
Age below 18 yo
Active infectious corneal disease
Post penetrating keratoplasty or glaucoma drainage device
Known allergy to medication
Lactation , Pregnant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
AssocProf Pinnita Tanthuvanit
Phone
02-4198036
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
AssocProf Pinnita Tanthuvanit, MD
Organizational Affiliation
Mahidol University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Ophthalmology , Siriraj Hospital
City
Bangkok
Country
Thailand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Assoc Prof Pinnita Tanthuvanit
12. IPD Sharing Statement
Learn more about this trial
Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma
We'll reach out to this number within 24 hrs